433 results on '"Dong, Haidong"'
Search Results
2. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial
3. Solid cancer-directed CAR T cell therapy that attacks both tumor and immunosuppressive cells via targeting PD-L1
4. A digital microfluidic device integrated with electrochemical sensor and 3D matrix for detecting soluble PD-L1
5. Single cell profiling at the maternal–fetal interface reveals a deficiency of PD-L1+ non-immune cells in human spontaneous preterm labor
6. Noncanonical TRAIL Signaling Promotes Myeloid-Derived Suppressor Cell Abundance and Tumor Growth in Cholangiocarcinoma
7. Effect of design parameters on degree of blending and performance of recycled hot-mix asphalt incorporating fine reclaimed asphalt pavement particles
8. Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity
9. Single cell RNA sequencing unravels mechanisms underlying senescence-like phenotypes of alveolar macrophages
10. Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in patients with severe COVID-19
11. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
12. Evaluation of PD-L1 and B7-H3 expression as a predictor of response to adjuvant chemotherapy in bladder cancer
13. T cell equation as a conceptual model of T cell responses for maximizing the efficacy of cancer immunotherapy
14. Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups
15. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
16. Regulation of sister chromatid cohesion by nuclear PD-L1
17. Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
18. Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
19. Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy
20. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 + T cells via ME1 up-regulation
21. TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
22. Immune resilience in response to cancer therapy
23. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome
24. BRAFV600E-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts
25. Costimulatory B7-H1 in Renal Cell Carcinoma Patients: Indicator of Tumor Aggressiveness and Potential Therapeutic Target
26. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
27. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression
28. FOXA1 overexpression suppresses interferon signaling and immune response in cancer
29. Carrying the torch & facing new challenges
30. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
31. Secreted ORF8 induces monocytic pro-inflammatory cytokines through NLRP3 pathways in severe patients with COVID-19
32. Abstract 6644: Investigating the effect of immune checkpoint inhibitors (ICI) on ovarian function in young patients with melanoma
33. Abstract 4160: Characterization of cytotoxic resilient T cells in patients with advanced cancers in response to salvage radiation therapy or chemotherapy
34. Master Transcription Factor Reprogramming Unleashes Selective Translation Promoting Castration Resistance and Immune Evasion in Lethal Prostate Cancer
35. Seeking and destroying the evils from the inside-translating cancer immunity to fight COVID-19
36. Circulating levels of PD-L1 and Galectin-9 are associated with patient survival in surgically treated Hepatocellular Carcinoma independent of their intra-tumoral expression levels
37. Reverse signaling via PD-L1 supports malignant cell growth and survival in classical Hodgkin lymphoma
38. A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
39. Cytokines and Immune Cell Phenotype in Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
40. PD-L1 interacts with CD80 to regulate graft-versusleukemia activity of donor [CD8.sup.+] T cells
41. Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1
42. Solid pavestones are needed to pave a solid way to success
43. Abstract A036: Surfaceome profiling of rhabdomyosarcoma reveals B7-H3 as a mediator of immune evasion
44. Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
45. Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
46. Abstract 1315: Tumor necrosis factor related apoptosis inducing ligand fosters myeloid derived suppressor cell mediated tumor immune evasion in cholangiocarcinoma
47. Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise
48. Single cell profiling at the maternal–fetal interface reveals a deficiency of PD-L1+ non-immune cells in human spontaneous preterm labor.
49. Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction
50. Rescuing Cancer Immunity by Plasma Exchange in Metastatic Melanoma (ReCIPE-M1): protocol for a single-institution, open-label safety trial of plasma exchange to clear sPD-L1 for immunotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.